Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Moderna 2Q Revenues Tumble | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Moderna 2Q Revenues Tumble

Reports loss of $1.3 billion in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Moderna
2Q Revenues: $241 million (-30%)
2Q Loss: $1.3 billion (loss of $1.4B 2Q23)
Comments: Decline in revenues is attributable to decreased sales of the Company’s COVID-19 vaccine. The company reported $184 million in Spikevax (COVID-19 vaccine) sales in the quarter, down 37%, which includes $162 million of U.S. sales and $22 million of international sales.
 
Cost of sales in the quarter was $115 million, which included third-party royalties of $10 million, unutilized manufacturing capacity and wind-down costs of $55 million, and inventory write-downs of $14 million. R&D expenses increased 6% in the quarter to $1.2 billion.
 
The company received U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July, and received EMA positive opinion in June. The vaccine is recommended for all unvaccinated people 75 and older and unvaccinated people ages 60-74 who are at increased risk for RSV.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters